IMPACT OF NICORANDIL IN ANGINA: SUBGROUP ANALYSES
Aims: IONA (impact of nicorandil in angina) is a randomised, double blind, placebo controlled trial of nicorandil, with a target dose of 20 mg twice daily. The consistency of benefits seen in subgroups is reported. Methods: The primary composite end point of the study was coronary heart disease deat...
Main Author: | IONA Study Group |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2010-08-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1468 |
Similar Items
-
PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY
by: A. V. Rudakova, et al.
Published: (2015-12-01) -
STUDY OF EFFECT PREKONDITSIONIRUYUSCHEGO RESVERATROL AND NICORANDIL IN THE CORRECTION OF ADMA-LIKE PRE-ECLAMPSIA
by: V. V. Gureev, et al.
Published: (2016-10-01) -
Sostoyanie kontrolya giperkholesterinemii u bol'nykh sakharnym diabetom i ishemicheskoy bolezn'yu serdtsa v usloviyakh ambulatornoy praktiki
by: Faragat Yusufovna Valikulova, et al.
Published: (2013-09-01) -
PROSPECTS OF USING THE COMBINED PREPARATION OF COLPOCID IN THE TREATMENT OF CERVICAL PATHOLOGY ASSOCIATED WITH HUMAN PAPILLOMAVIRUS
by: Ольга Юрьевна Цыганкова, et al.
Published: (2018-01-01) -
RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
by: N. F. Puchinyan, et al.
Published: (2016-01-01)